Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An update from KalVista Pharmaceuticals ( (KALV) ) is now available.
KalVista Pharmaceuticals has appointed Laurence Reid, Ph.D., to its Board of Directors, highlighting his extensive leadership experience in biotechnology. Dr. Reid’s addition is timely as KalVista progresses its novel treatment, sebetralstat, towards global market approval. This appointment comes amidst strategic efforts to transition the company into a commercial organization, aiming to bring transformative oral medicines for rare diseases to the market.
See more insights into KALV stock on TipRanks’ Stock Analysis page.
